Big Guy v. Little Guy
Executive SummaryIt started off as a perfect relationship: diagnostic giant Boehringer Mannheim and tiny Igen would jointly develop an immunoassay analyzer based on Igen's impressive new electrochemiluminesence (ECL) technology. Now the two companies find themselves in court, with Igen charging, among other things, that BMC didn't calculate royalties fairly and BMC seeking to retain rights to sell the ECL analyzer.
You may also be interested in...
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.